Welcome to our dedicated page for AC Immune SA SEC filings (Ticker: ACIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AC Immune SA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AC Immune SA's regulatory disclosures and financial reporting.
AC Immune SA (ACIU) reported positive interim results from a first-in-human Phase 1/1b trial of ACI-19764, its wholly owned, orally administered small-molecule inhibitor of the NLRP3 inflammasome. In healthy volunteers, ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts, including single doses up to 20mg per day, with a serum half-life greater than 30 hours, no serious adverse events and no treatment withdrawals. Cerebrospinal fluid data showed clear brain penetration, and daily doses at or below 10mg achieved pharmacokinetic concentrations above the IC90 with dose-dependent inhibition of IL‑1β release. A Phase 1b cohort in patients with cardiovascular risk, defined by elevated hsCRP plus type 2 diabetes and/or obesity, is now dosing, with initial results expected by year end and full Phase 1/1b data expected in the first half of 2027.
AC Immune SA reports that the U.S. FDA has granted Fast Track designation and cleared the IND application for its wholly owned anti‑alpha‑synuclein active immunotherapy ACI‑7104 for early‑stage Parkinson’s disease. ACI‑7104 is designed to induce alpha‑synuclein‑specific antibodies that preferentially recognize aggregated, neuron‑toxic species.
The therapy is being evaluated in the adaptive, biomarker‑based VacSYn Phase 2 trial, with final Part 1 week‑100 results expected in H2 2026. Interim Part 1 data at 76 weeks showed ACI‑7104 was safe and well tolerated, achieved a 100% immunogenicity responder rate, and provided early signals of activity. A $4 million research grant from the Vijay and Marie Goradia Charitable Foundation supports extending Part 1 for an additional two years to assess long‑term safety and efficacy.
AC Immune SA reported first-half 2026 contract revenue of CHF 16.2 million, up from CHF 2.3 million mainly from Takeda and Lilly milestones, while IFRS net loss narrowed to CHF 12.9 million versus CHF 40.2 million a year earlier.
Research and development expenses declined to CHF 22.2 million after 2025 portfolio prioritization, and operating cash outflow improved to CHF 15.6 million. Liquidity totaled CHF 75.4 million in cash and short‑term financial assets, which the company believes will be sufficient to meet projected operating requirements through Q4 2027.
Collaboration activity was strong: a USD 12 million Takeda milestone for the ABATE trial and CHF 11.0 million from a Lilly Tau Morphomer amendment drove revenue, and short‑term deferred contract revenue reached CHF 89.5 million. Wholly owned programs ACI‑7104 and ACI‑19764 are expected to deliver Phase 2 and Phase 1 data in H2 2026.
AC Immune reported interim 12‑month data from the first three prodromal Alzheimer’s disease cohorts (AD1–AD3) of the Phase 1b/2 ABATE trial, covering 74 patients treated with its anti‑amyloid beta active immunotherapy ACI‑24. The therapy has been generally safe and well tolerated so far, with no amyloid‑related imaging abnormalities‑edema (ARIA‑E) observed and anti‑Abeta antibody responses detected at all dose levels with a dose response. The company is now testing an enhanced ACI‑24 formulation with an additional adjuvant in the newly initiated Cohort AD4 to further boost immunogenicity. Under its existing option and license agreement with Takeda for anti‑Abeta active immunotherapies, AC Immune received an upfront payment of $100 million and a $12 million milestone on dosing the first patients in Cohort AD4, and may earn up to approximately $2.1 billion in additional milestones plus tiered double‑digit royalties if the program advances to commercialization.
AC Immune SA director Roy Ervin Twyman received equity awards as compensation. On June 11, 2026 he was granted 16,568 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan, increasing his holdings to 92,556 common shares, including 66,556 shares underlying outstanding restricted share units.
On the same date he also received share options over 38,889 common shares with an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036, giving him the right to buy the underlying shares in the future rather than reflecting an open-market purchase.
AC Immune SA director Renee Aguiar-Lucander reported equity compensation awards rather than open-market trades. On June 11, 2026, she received a restricted share unit grant covering 16,568 common shares under the AC Immune SA 2016 Stock Option and Incentive Plan.
Following this grant, 51,136 common shares are underlying her outstanding restricted share units. She was also awarded options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036.
AC Immune SA interim CEO Martin Zuegel reported equity compensation awards. On June 11, 2026, he received a grant of 33,136 restricted share units under the company’s 2016 Stock Option and Incentive Plan. Following this award, he holds 71,408 common shares underlying outstanding restricted share units.
On the same date, he was also granted share options on 77,778 common shares at an exercise price of $2.6200 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. All reported holdings are direct.
AC Immune SA director Monika Buetler received new equity awards as part of her compensation. On June 11, 2026, she was granted 17,751 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan. The grant increases her direct interest in the company without any cash purchase.
On the same date, she also received share options for 41,667 common shares at an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. After these awards, she directly holds 71,656 common shares, largely reflecting restricted share units rather than open-market buying.
AC Immune SA director June Carl Howard reported new equity compensation grants. On June 11, 2026, she received 16,568 common shares as a restricted share unit grant under the AC Immune SA 2016 Stock Option and Incentive Plan.
Following this award, her direct holdings in common shares were 67,556. She also received share options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036. These awards reflect compensation rather than open‑market trading.
AC Immune SA reported that shareholders approved all proposals at the June 2026 Annual General Meeting, including the 2025 IFRS consolidated and statutory financial statements and the 2025 compensation report. Shareholders also discharged the Board and Executive Management and approved maximum compensation of CHF 1.029M for the Board and CHF 6.742M for Executive Management.
The company recorded a 2025 IFRS loss of CHF 70.4M on revenue of CHF 3.6M, increasing accumulated losses brought forward to CHF 424.441M. Liquidity was CHF 91.4M at year-end 2025 and CHF 74.8M as of March 31, 2026, supporting guidance for a cash runway into Q4 2027 with 2026 cash burn of CHF 55–65M. Shareholders approved a new capital band allowing share capital changes between CHF 2,202,018.50 and CHF 2,862,500.00 until June 11, 2031, and increased conditional share capital for employee plans to CHF 150,000.00 (up to 7.5 million shares). The AGM presentation highlighted an Alzheimer’s and Parkinson’s-focused pipeline, multiple FDA Fast Track designations and planned 2026 clinical milestones.